Gabapentin — sold under the brand name Neurontin — was approved by the FDA to treat partial onset seizures in people with epilepsy. That single approval launched one of the most remarkable stories in modern prescribing. Today, up to 95% of gabapentin prescriptions are written for conditions the drug was never officially approved to treat, spanning everything from anxiety and insomnia to chronic back pain and hot flashes. It is one of the most widely prescribed medications in the United States, and the vast majority of patients taking it are using it off-label. This isn’t a fringe practice.
One in five prescriptions written in the U.S. today is for off-label use, according to the Agency for Healthcare Research and Quality, and gabapentin sits near the top of that list. By 2001, 83% of gabapentin prescriptions were already being written for non-seizure conditions, a figure that has only climbed since. For families navigating dementia care, brain health concerns, or chronic neurological conditions, gabapentin’s name comes up constantly — sometimes helpfully, sometimes not. This article breaks down exactly what gabapentin is approved for, the dozen-plus conditions it treats off-label, where the evidence is solid, and where it falls short.
Table of Contents
- How Did a Drug Approved for Seizures End Up Treating 12+ Other Conditions?
- The Full List of Off-Label Uses — and Which Ones Actually Have Evidence
- Why Gabapentin Keeps Showing Up in Dementia and Brain Health Conversations
- Gabapentin vs. Other Options — What Caregivers Should Weigh
- The Risks of Off-Label Prescribing That Nobody Talks About
- What to Ask Your Doctor Before Starting Gabapentin Off-Label
- The Future of Off-Label Prescribing and What It Means for Brain Health
- Conclusion
- Frequently Asked Questions
How Did a Drug Approved for Seizures End Up Treating 12+ Other Conditions?
The story starts with how gabapentin works in the brain. Designed to mimic the neurotransmitter GABA, gabapentin actually binds to a specific subunit of voltage-gated calcium channels in the central nervous system. This mechanism reduces the release of excitatory neurotransmitters, which is why it stops seizures — but it also means the drug calms overactive nerve signaling more broadly. Physicians noticed early on that patients taking gabapentin for epilepsy reported improvements in pain, sleep, and anxiety. Those clinical observations opened the door to off-label experimentation. Off-label prescribing is completely legal.
The FDA regulates how pharmaceutical companies market and label drugs, but it does not regulate the practice of medicine itself. Once a drug is approved for any condition, a physician may prescribe it for any other condition based on their clinical judgment. The American Medical Association’s Journal of Ethics has affirmed this distinction repeatedly. So when doctors observed gabapentin helping with nerve pain or calming anxiety symptoms, they were free to prescribe it for those purposes — even without formal FDA trials backing up those specific uses. The result is a drug with a remarkably wide footprint. Gabapentin’s FDA-approved indications are narrow: adjunctive therapy for partial onset seizures in adults and children over three, postherpetic neuralgia in adults (added in 2002), and restless legs syndrome (approved for the extended-release form, Horizant). Compare that slim label to the sprawling list of off-label uses that now dominate its prescribing, and you begin to see why gabapentin has become a case study in how modern medicine actually works versus how most people assume it works.
The Full List of Off-Label Uses — and Which Ones Actually Have Evidence
Gabapentin is commonly prescribed off-label for diabetic neuropathy, generalized anxiety disorder, social anxiety disorder, bipolar disorder, migraine headache prophylaxis, fibromyalgia, chronic lower back pain and sciatica, insomnia and sleep disorders, menopausal and chemotherapy-induced hot flashes, alcohol use disorder and alcohol withdrawal, trigeminal neuralgia, complex regional pain syndrome, phantom limb pain, periodic limb movement disorder of sleep, premenstrual syndrome, PTSD-related symptoms, and essential tremor. That is well over a dozen distinct conditions, each with its own body of clinical literature — some robust, some thin. However, the quality of evidence varies enormously across these uses. According to a review published in the journal Substance Abuse, in the majority of off-label circumstances gabapentin is not the optimal treatment. Reviews examining off-label indications such as migraine, fibromyalgia, mental illness, and substance dependence have found modest to no effect on relevant clinical outcomes.
The strongest evidence supports off-label use for diabetic neuropathy and migraine prophylaxis, where multiple clinical trials have demonstrated meaningful benefit. For conditions like bipolar disorder or PTSD symptoms, the data is far weaker, and patients and caregivers should approach those uses with appropriate skepticism. This is an important distinction for anyone in the dementia care space. If a loved one’s physician suggests gabapentin for agitation, anxiety, or sleep problems associated with cognitive decline, it is reasonable to ask which category of evidence supports that particular use. A drug being prescribed off-label is not inherently wrong — but it does mean the usual safety net of large-scale fda trials may not exist for that specific application.
Why Gabapentin Keeps Showing Up in Dementia and Brain Health Conversations
For families dealing with dementia, gabapentin often enters the picture through the side door. A person with Alzheimer’s disease may develop neuropathic pain, restless legs, or severe insomnia — all conditions where gabapentin is a common prescription. Because many dementia patients are already on multiple medications, physicians sometimes favor gabapentin for its relatively mild drug interaction profile compared to alternatives like opioids or benzodiazepines. In an older adult who cannot safely take certain sedatives, gabapentin for insomnia may seem like a reasonable compromise. But gabapentin carries its own risks in elderly populations. Side effects include dizziness, drowsiness, and impaired coordination — all of which increase fall risk, a serious concern for anyone with cognitive impairment.
The drug can also cause confusion and cognitive dulling, which in a dementia patient may be difficult to distinguish from disease progression. A caregiver who notices their loved one becoming more confused or unsteady after starting gabapentin should raise this with the prescribing physician rather than assuming it is simply the dementia getting worse. There is also growing concern about gabapentin misuse. The drug has been reclassified as a Schedule V controlled substance in several U.S. states due to its potential for abuse, particularly when combined with opioids. While this is less of a concern in supervised dementia care settings, it reflects a broader shift in how the medical community views gabapentin — no longer as the harmless, non-addictive alternative it was once marketed as.
Gabapentin vs. Other Options — What Caregivers Should Weigh
When a physician proposes gabapentin for an off-label use, it helps to understand what the alternatives are and why gabapentin is being chosen over them. For neuropathic pain, the main competitors are pregabalin (Lyrica), duloxetine (Cymbalta), and tricyclic antidepressants like amitriptyline. Pregabalin works through a similar mechanism and is actually FDA-approved for diabetic neuropathy, fibromyalgia, and postherpetic neuralgia — making it a more formally validated choice for several conditions where gabapentin is used off-label. The tradeoff is often cost: gabapentin is available as a cheap generic, while pregabalin, though now also generic, historically cost significantly more. For anxiety, gabapentin competes with SSRIs, SNRIs, buspirone, and benzodiazepines.
The appeal of gabapentin in this context is that it lacks the dependency risk of benzodiazepines and avoids the sexual side effects common with SSRIs. However, the evidence for gabapentin in generalized or social anxiety disorder is substantially weaker than for established first-line treatments. Choosing gabapentin for anxiety typically makes the most sense when a patient has already tried and failed — or cannot tolerate — standard options. For insomnia, gabapentin’s sedating properties make it attractive, but dedicated sleep medications or cognitive behavioral therapy for insomnia (CBT-I) generally have stronger evidence. The decision often comes down to what else the patient is dealing with. If someone has both neuropathic pain and insomnia, gabapentin can address both with a single pill — a practical advantage that matters in populations already managing complex medication regimens.
The Risks of Off-Label Prescribing That Nobody Talks About
The most underappreciated risk of off-label prescribing is not medical — it is informational. When a drug is prescribed for its FDA-approved use, the patient can read the drug’s official labeling, find clinical trial data, and understand what evidence supports the treatment. When a drug is prescribed off-label, that infrastructure largely disappears. The patient insert does not mention their condition. The dosing may be based on small studies or clinical experience rather than large trials. Insurance may not cover the prescription, or may require prior authorization that delays treatment. For gabapentin specifically, the evidence gap creates real problems.
A physician prescribing gabapentin for fibromyalgia is making a judgment call based on mixed data — some trials show modest benefit, while others show no significant difference from placebo. The patient, trusting their doctor’s recommendation, may not realize that the evidence beneath this particular prescription is substantially thinner than what they would expect from a medication being confidently recommended. This is not an argument against off-label use, but it is an argument for transparency. There is also a systemic concern. Pharmaceutical companies cannot legally promote drugs for off-label uses, but the line between education and promotion has been contested repeatedly. Pfizer paid $430 million in 2004 to settle allegations that it had illegally promoted gabapentin for off-label uses including bipolar disorder and pain. This history does not mean every off-label gabapentin prescription is inappropriate — many are medically reasonable — but it does mean the popularity of certain off-label uses was shaped by forces beyond pure clinical evidence.
What to Ask Your Doctor Before Starting Gabapentin Off-Label
If gabapentin is being recommended for you or a family member for a non-seizure condition, a few direct questions can clarify the situation. Ask whether the drug is being prescribed on-label or off-label. Ask what evidence supports this particular use — is it based on randomized controlled trials, smaller studies, or primarily clinical experience? Ask whether there is an FDA-approved alternative for the same condition and, if so, why gabapentin is being chosen instead.
And ask about a realistic timeline: how long before you should expect to see benefit, and what would prompt a decision to stop or switch. These questions are not confrontational. They are the kind of informed engagement that leads to better outcomes, particularly for older adults and dementia patients who may be less able to advocate for themselves. A physician comfortable with their prescribing decision will welcome the conversation.
The Future of Off-Label Prescribing and What It Means for Brain Health
The gabapentin story is not unique — it is a window into how the entire pharmaceutical system operates. Off-label prescribing accounts for roughly 25% of all central nervous system medication use, the highest rate of any therapeutic class. As the population ages and neurodegenerative diseases become more prevalent, the pressure to repurpose existing drugs for brain health conditions will only grow.
Gabapentin’s trajectory — from narrow epilepsy drug to ubiquitous off-label prescription — previews what may happen with other medications as researchers and clinicians search for treatments that Alzheimer’s, Parkinson’s, and other conditions desperately need. The challenge going forward is ensuring that off-label use is guided by evidence rather than momentum. Just because a drug has been prescribed off-label for twenty years does not mean it is the best option. Ongoing research, honest conversations between patients and physicians, and a willingness to revisit prescribing habits will determine whether off-label use remains a valuable tool or becomes a shortcut that substitutes familiarity for rigor.
Conclusion
Gabapentin was approved to treat seizures, but 95% of its prescriptions today are for something else entirely — from nerve pain and anxiety to insomnia and hot flashes. That gap between a drug’s official label and its real-world use is one of the most important and least understood aspects of modern medicine. For caregivers and patients navigating brain health challenges, understanding off-label prescribing is not optional. It is essential context for every conversation with a physician and every medication decision. The key takeaway is not that off-label prescribing is inherently good or bad.
It is that evidence quality varies dramatically depending on the condition being treated. Gabapentin for diabetic neuropathy rests on solid clinical trial data. Gabapentin for bipolar disorder does not. Knowing the difference — and being willing to ask — is what separates informed care from passive compliance. Talk with your doctor, ask about the evidence, and make sure any medication your loved one takes is earning its place in the regimen.
Frequently Asked Questions
Is it legal for my doctor to prescribe gabapentin for something it wasn’t approved for?
Yes. Off-label prescribing is entirely legal. The FDA regulates how drug companies market medications, not how physicians practice medicine. Doctors can prescribe any approved drug for any condition based on their clinical judgment. According to the AMA Journal of Ethics, this is a well-established aspect of medical practice.
How common is off-label prescribing in the United States?
Very common. According to the Agency for Healthcare Research and Quality, one in five prescriptions written in the U.S. is for off-label use. The rate is highest for central nervous system medications, where off-label prescribing reaches approximately 25% of all prescriptions in that category.
What off-label uses of gabapentin have the strongest evidence?
The most robust evidence supports gabapentin’s off-label use for diabetic neuropathy and migraine prophylaxis. These uses are backed by multiple clinical trials showing meaningful benefit. Evidence for other uses — including anxiety, bipolar disorder, and fibromyalgia — ranges from modest to weak.
Is gabapentin addictive?
Gabapentin was long considered non-addictive, but that view has changed. Several U.S. states have reclassified gabapentin as a Schedule V controlled substance due to growing evidence of misuse potential, particularly when combined with opioids. While the risk is lower than with benzodiazepines or opioids, it is no longer considered negligible.
Should I be concerned if my elderly parent with dementia is prescribed gabapentin?
It depends on the indication and the alternatives. Gabapentin can cause dizziness, drowsiness, confusion, and impaired coordination — side effects that overlap with and can worsen dementia symptoms. If a loved one becomes more confused or unsteady after starting gabapentin, raise this with their physician. The medication may still be appropriate, but these effects should be monitored closely.
Can gabapentin help with dementia-related agitation or anxiety?
Some physicians prescribe gabapentin off-label for agitation or anxiety in dementia patients, but the evidence supporting this specific use is limited. First-line approaches for dementia-related behavioral symptoms typically involve non-pharmacological interventions, and when medication is needed, other drug classes are usually tried first. Ask your doctor what evidence supports gabapentin for your loved one’s particular symptoms.
